Methylation of tumor suppressor genes in ovarian cancer

Ozdemir,Filiz; Altinisik,Julide; Karateke,Ates; Coksuer,Hakan; Buyru,Nur

doi:10.3892/etm.2012.715

Methylation of tumor suppressor genes in ovarian cancer

Authors:
- Filiz Ozdemir
- Julide Altinisik
- Ates Karateke
- Hakan Coksuer
- Nur Buyru
View Affiliations

Affiliations: Department of Medical Biology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, Department of Gynecology and Obstetrics, Zeynep Kamil Maternity and Child Research and Training Hospital, Istanbul, Turkey
Published online on: September 18, 2012 https://doi.org/10.3892/etm.2012.715
Pages: 1092-1096

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant methylation of gene promoter regions is one of the mechanisms for inactivation of tumor suppressor genes in human malignancies. In this study, the methylation pattern of 24 tumor suppressor genes was analyzed in 75 samples of ovarian cancer using the methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay. Of the 24 tumor suppressor genes examined, aberrant methylation was observed in 17. The three most frequently methylated genes were CDKN2B, CDH13 and RASSF1, followed by ESR1 and MLH1. Methylation frequencies ranged from 1.3% for CDKN2A, RARβ, CASP8, VHL and TP73 to 24% for CDKN2B. The corresponding normal DNA from each patient was also investigated. Methylation was detected in tumors, although not in normal tissues, with the exception of two samples, indicating aberrant methylation in tumors. Clear cell carcinoma samples exhibited a higher frequency of CDKN2B promoter hypermethylation compared to those of other histological types (P=0.05). Our data indicate that methylation of the CDKN2B gene is a frequent event in ovarian carcinogenesis and that analysis of only three genes is sufficient to detect the presence of methylation in 35% of ovarian cancer cases. However, more studies using a much larger sample size are needed to define the potential role of DNA methylation as a marker for ovarian cancer.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin. 57:43–66. 2007.
2	Clark TG, Stewart ME, Altman DG, Gabra H and Smyth JF: A prognostic model for ovarian cancer. Br J Cancer. 85:944–952. 2001. View Article : Google Scholar : PubMed/NCBI
3	Baylin SB and Herman JG: DNA methylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
4	Jones PA: DNA methylation errors and cancer. Cancer Res. 56:2463–2467. 1996.PubMed/NCBI
5	Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
6	Wilson AS, Power BE and Molloy PL: DNA hypomethylation and human diseases. Biochem Biophys Acta. 1775:138–162. 2007.PubMed/NCBI
7	Jones PA: The DNA methylation paradox. Trends Genet. 15:34–37. 1999. View Article : Google Scholar
8	Lund AH and van Lohuizen M: Epigenetics and cancer. Genes Dev. 18:2315–2335. 2004. View Article : Google Scholar : PubMed/NCBI
9	Laird PW: Cancer epigenetics. Hum Mol Genet. 14:R65–R76. 2005. View Article : Google Scholar
10	Ducasse M and Brown MA: Epigenetic aberrations and cancer. Mol Cancer. 5:602006. View Article : Google Scholar
11	Paluszczak J and Baer-Dubowska W: Epigenetic diagnostics of cancer - the application of DNA methylation markers. J Appl Genet. 47:365–375. 2006. View Article : Google Scholar : PubMed/NCBI
12	Barton CA, Hacker NF, Clark SJ and O’Brien PM: DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol. 109:129–139. 2008. View Article : Google Scholar : PubMed/NCBI
13	Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA and Welcsh P: Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. 8:482009. View Article : Google Scholar : PubMed/NCBI
14	Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL and Cairns P: Tumor cell-specific BRCA1 and RASSF1A hyper-methylation in serum, plasma and peritoneal fluid from ovarian cancer patients. Cancer Res. 64:6476–6481. 2004.PubMed/NCBI
15	Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF and Schorge JO: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res. 11:5365–5369. 2005. View Article : Google Scholar : PubMed/NCBI
16	Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA and Gazdar AF: Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res. 8:3324–3331. 2002.PubMed/NCBI
17	Yuecheng Y, Hongmei L and Xiaoyan X: Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis. 23:65–74. 2006. View Article : Google Scholar : PubMed/NCBI
18	Tam KF, Liu VW, Liu SS, Tsang PC, Cheung AN, Yip AM and Ngan HY: Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol. 133:331–341. 2007. View Article : Google Scholar : PubMed/NCBI
19	Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J and Brown R: Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol. 158:1121–1127. 2001. View Article : Google Scholar
20	Kiwerska K, Rydzanicz M, Kram A, Pastok M, Antkowiak A, Domagala W and Szyfter K: Mutational analysis of CDKN2A gene in a group of 390 larynx cancer patients. Mol Biol Rep. 37:325–332. 2010. View Article : Google Scholar : PubMed/NCBI
21	Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O’Dorisio MS, Held WA, Cavenee WK and Plass C: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 24:132–138. 2000. View Article : Google Scholar : PubMed/NCBI
22	Mehrotra J, Ganpat MM, Kanan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T, Garrett E, Parmigiani G, Broome C and Sukumar S: Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res. 10:2052–2057. 2004. View Article : Google Scholar
23	Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP and Errami A: Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 33:e1282005. View Article : Google Scholar : PubMed/NCBI
24	Warnecke PM and Bestor TH: Cytosine methylation and human cancer. Curr Opin Oncol. 12:68–73. 2000. View Article : Google Scholar : PubMed/NCBI
25	El-Osta A, Baker EK and Wolffe AP: Profiling methyl-CpG specific determinants on transcriptionally silent chromatin. Mol Biol Rep. 28:209–215. 2001. View Article : Google Scholar : PubMed/NCBI
26	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
27	Esteller M, Corn PG, Baylin SB and Herman JG: A gene hyper-methylation profile of human cancer. Cancer Res. 61:3225–3229. 2001.PubMed/NCBI
28	Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D, Brown I, Williams AR, Bates PA, Smyth JF and Garba H: OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet. 34:337–343. 2003. View Article : Google Scholar : PubMed/NCBI
29	Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G and Brown R: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 65:8961–8967. 2005. View Article : Google Scholar : PubMed/NCBI
30	Wakana K, Akiyama Y, Aso T and Yuasa Y: Involvement of GATA-4/5 transcription factors in ovarian carcinogenesis. Cancer Lett. 241:281–288. 2006. View Article : Google Scholar : PubMed/NCBI
31	Milde-Langosch K, Ocon E, Becker G and Löning T: p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer. 79:61–65. 1998. View Article : Google Scholar : PubMed/NCBI
32	Kudoh K, Ichikawa Y, Yoshida S, Hirai M, Kikuchi Y, Nagata I, Miwa M and Uchida K: Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int J Cancer. 99:579–582. 2002. View Article : Google Scholar : PubMed/NCBI
33	Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B, Whitaker R, Lee PS, Elkins-Williams T, Bentley RC, Marks JR and Berchuck A: Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev. 17:585–593. 2008. View Article : Google Scholar : PubMed/NCBI
34	Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH and An HJ: Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gynecol Pathol. 30:205–217. 2011. View Article : Google Scholar : PubMed/NCBI
35	Drexler HG: Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 12:845–859. 1998. View Article : Google Scholar : PubMed/NCBI
36	Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan HY: Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer. 6:2122006. View Article : Google Scholar : PubMed/NCBI
37	Fujita M, Enomoto T, Haba T, Nakashima R, Sasaki M, Yoshino K, Wada H, Buzard GS, Matsuzaki N, Wakasa K and Murata Y: Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer. 74:148–155. 1997. View Article : Google Scholar : PubMed/NCBI
38	Dodge JE, Munson C and List AF: KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. Leukemia Res. 25:917–925. 2001. View Article : Google Scholar : PubMed/NCBI
39	Aggerholm A, Guldberg P, Hokland M and Hokland P: Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res. 59:436–441. 1999.PubMed/NCBI
40	Herman JG, Jen J, Merlo A and Baylin SB: Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56:722–727. 1996.PubMed/NCBI
41	Wang Y, Zhang D, Zheng W, Luo J, Bai Y and Lu Z: Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer. 112:1325–1336. 2008. View Article : Google Scholar : PubMed/NCBI
42	Buyru N, Altinisik J, Ozdemir F, Demokan S and Dalay N: Methylation profiles in breast cancer. Cancer Invest. 27:307–312. 2009. View Article : Google Scholar
43	Liu Z, Wang LE, Wang L, Lu KH, Mills GB, Bondy ML and Wei Q: Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res. 11:4968–4976. 2005. View Article : Google Scholar : PubMed/NCBI
44	Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI and Shridhar V: Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol. 15:715–720. 1999.PubMed/NCBI
45	Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD and Gazdar AF: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 61:4556–4560. 2001.PubMed/NCBI
46	Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z and Lind GE: DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer. 6:452007. View Article : Google Scholar : PubMed/NCBI
47	Dammann R, Schagdarsurengin U, Seidal C, Strunnikova M, Rastetter M, Baier K and Pfeifer GP: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 20:645–663. 2005.PubMed/NCBI
48	Yoon JH, Dammann R and Pfeifer GP: Hypermethylation of the CpG island of RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer. 94:212–217. 2001. View Article : Google Scholar : PubMed/NCBI
49	Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER and Latif F: Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumors. Oncogene. 20:1509–1518. 2001. View Article : Google Scholar : PubMed/NCBI